<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742989</url>
  </required_header>
  <id_info>
    <org_study_id>KCUMB-2005-01</org_study_id>
    <nct_id>NCT00742989</nct_id>
  </id_info>
  <brief_title>Effect of Osteopathic Lymphatic Treatment on Plasma Volume, Protein Concentration and Albumin Concentration.</brief_title>
  <official_title>The Short-Term Effect of Osteopathic Lymphatic Treatment on Blood Cell Count, Plasma Protein, and Blood Pressure: A Pilot Study in a Cross-Over Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kansas City University of Medicine and Biosciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kansas City University of Medicine and Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this project is to see how much an osteopathic lymphatic treatment (OLT) causes
      an increase in plasma volume, total plasma protein concentration, and albumin concentration.
      This is an important step in understanding the effects of OLT, specifically its effects on
      fluid in the body. The primary role of the lymph system is the return of fluid and proteins
      lost from the blood vessels. Despite this, no research has been done to see what effects an
      OLT has on fluid and protein levels in the blood.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline blood pressure</measure>
    <time_frame>15 minute</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma proteins</measure>
    <time_frame>15 minute</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OLT administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>placebo-OLT</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OLT maneuver</intervention_name>
    <description>direct myofascial release for the thoracic inlet for 30 seconds, supine rib raising for 1 minute on each side of the body, thoracic pumping for one minute, thoracic vacuum for 30 seconds, doming of the abdominal diaphragm for 30 seconds, abdominal pumping for 1 minute, pedal pumping for 1 minute, a second thoracic pump for 1 minute, a second thoracic vacuum for 30 seconds, and a final direct myofascial release for the thoracic inlet lasting 30 seconds</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham OLT</intervention_name>
    <description>Therapeutic massage performed</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal, healthy volunteers

          -  Males

          -  Age 20 to 40 years

        Exclusion Criteria:

          -  History of cardiovascular, kidney, or liver disease.

          -  Cannot have taken medication or drugs or have been ill at the time of the study or for
             two weeks prior.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. Evan Rivers, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kansas City University of Medicine and Biosciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charlott L. Williiams, RN, CCRC</last_name>
    <role>Study Director</role>
    <affiliation>Kansas City University of Medicine and Biosciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan G. Glaros, PhD</last_name>
    <role>Study Director</role>
    <affiliation>KCUMB</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Treffer, DO</last_name>
    <role>Study Chair</role>
    <affiliation>KCUMB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dybedal Clinical Research Center, Kansas City University of Medicine and Biosciences</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kcumb.edu/dybedalcrc</url>
    <description>Dybedal Clinical Research Center</description>
  </link>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2008</study_first_submitted>
  <study_first_submitted_qc>August 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2008</study_first_posted>
  <last_update_submitted>August 27, 2008</last_update_submitted>
  <last_update_submitted_qc>August 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Patrick G. Clay, PharmD, Director, Dybedal Center for Clinical Research</name_title>
    <organization>Kansas City University of Medicine and Biosciences</organization>
  </responsible_party>
  <keyword>osteopathic</keyword>
  <keyword>lymphatic</keyword>
  <keyword>treatment</keyword>
  <keyword>OLT</keyword>
  <keyword>normal</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

